Effects of sitagliptin on lipid profiles in patients with type 2 diabetes mellitus: A meta-analysis of randomized clinical trials

Medicine (United States)

Volumn 95, Issue 2, 2016, Pages

  Fan, Minhua ^a   Li, Yuelan ^a   Zhang, Shihong ^a  

^a LIAOCHENG PEOPLE'S HOSPITAL   (China)

Author keywords

[No Author keywords available]

Indexed keywords

DIPEPTIDYL PEPTIDASE IV INHIBITOR; LIPID; SITAGLIPTIN;

BLOOD; COMPLICATION; DIABETES MELLITUS, TYPE 2; DRUG EFFECTS; DYSLIPIDEMIAS; HUMAN; LIPID METABOLISM; META ANALYSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC);

DIABETES MELLITUS, TYPE 2; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; DYSLIPIDEMIAS; HUMANS; LIPID METABOLISM; LIPIDS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SITAGLIPTIN PHOSPHATE;

EID: 84958152356     PISSN: 00257974     EISSN: 15365964     Source Type: Journal    
DOI: 10.1097/MD.0000000000002386     Document Type: Article

References (35)

1. Gaede P, Lund-Andersen H, Parving HH, et al. Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med. 2008;358:580-591.
2. Tan CE, Chew LS, Chio LF, et al. Cardiovascular risk factors and LDL subfraction profile in Type 2 diabetes mellitus subjects with good glycaemic control. Diabetes Res Clin Pract. 2001;51:107-114.
3. Chehade JM, Gladysz M, Mooradian AD. Dyslipidemia in type 2 diabetes: prevalence, pathophysiology, and management. Drugs. 2013;73:327-339.
4. Deacon CF, Holst JJ. Dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes: comparison, efficacy and safety. Expert Opin Pharmacother. 2013;14:2047-2058.
5. Monami M, Lamanna C, Desideri CM, et al. DPP-4 inhibitors and lipids: systematic review and meta-analysis. Adv Ther. 2012;29: 14-25.
6. Gallwitz B. Sitagliptin: profile of a novel DPP-4 inhibitor for the treatment of type 2 diabetes. Drugs Today (Barc). 2007;43:13-25.
7. Kubota A, Maeda H, Kanamori A, et al. Pleiotropic effects of sitagliptin in the treatment of type 2 diabetes mellitus patients. J Clin Med Res. 2012;4:309-313.
8. Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med. 2009;151:264-269W64.
9. Higgins JPT, Green S, eds. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011].
10. The Cochrane Collaboration, 2011. Available at: www.cochrane-handbook.org. Accessed July 06, 2015.
11. Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics. 1994;50:1088-1101.
12. Egger M, Davey Smith G, Schneider M, et al. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315:629-634.
13. Rosenstock J, Brazg R, Andryuk PJ, et al. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglita-zone therapy in patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Clin Ther. 2006;28:1556-1568.
14. Charbonnel B, Karasik A, Liu J, et al. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metfor-min therapy in patients with type 2 diabetes inadequately controlled with metformin alone. Diabetes Care. 2006;29:2638-2643.
15. Scott R, Loeys T, Davies MJ, et al. Efficacy and safety of sitagliptin when added to ongoing metformin therapy in patients with type 2 diabetes. Diabetes Obes Metab. 2008;10:959-969.
16. Williams-Herman D, Johnson J, Teng R, et al. Efficacy and safety of sitagliptin and metformin as initial combination therapy and as monotherapy over 2 years in patients with type 2 diabetes. Diabetes Obes Metab. 2010;12:442-451.
17. Yoon KH, Shockey GR, Teng R, et al. Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and pioglitazone on glycemic control and measures of beta-cell function in patients with type 2 diabetes. Int J Clin Pract. 2011;65:154-164.
18. Oz O, Kiyici S, Ersoy C, et al. Effect of sitagliptin monotherapy on serum total ghrelin levels in people with type 2 diabetes. Diabetes Res Clin Pract. 2011;94:212-216.
19. Fang WJ, Jian WX, Hu JF, et al. Effect of sitagliptin combined insulin on 46 patients with patients with type 2 diabetes mellitus. Chinese J New Drugs Clin Remedies. 2012;31:557-560.
20. Li L, Han P. Hypoglycemic effect of sitagliptin on type 2 diabetes and its protection of islet function. Pract Pharm Clin Remedies. 2013;16:696-698.
21. Derosa G, Ragonesi PD, Fogari E, et al. Sitagliptin added to previously taken antidiabetic agents on insulin resistance and lipid profile: a 2-year study evaluation. Fundam Clin Pharmacol. 2014;28:221-229.
22. Lv SS, Pan TR, Zhong X, et al. Effect of sitagliptin combined with metformin on insulin resistance, blood lipids and blood pressure in patients with type 2 diabetes mellitus. Acta Univ Med Anhui. 2014;49:103-109.
23. Pei LL, Sun ZH, Li Z, et al. Effects of sitagliptin combined with high-dose insulin on type 2 diabetes mellitus. J Shandong Univ. 2015;53:39-42.
24. Karim MN, Ahmed KR, Bukht MS, et al. Pattern and predictors of dyslipidemia in patients with type 2 diabetes mellitus. Diabetes Metab Syndr. 2013;7:95-100.
25. Genest J, Frohlich J, Fodor G, et al. Recommendations for the management of dyslipidemia and the prevention of cardiovascular disease: summary of the 2003 update. CMAJ. 2003;169:921-924.
26. Stone NJ, Robinson JG, Lichtenstein AH, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2014;63:2889-2934.
27. Barbieri M, Rizzo MR, Marfella R, et al. Decreased carotid atherosclerotic process by control of daily acute glucose fluctuations in diabetic patients treated by DPP-IV inhibitors. Atherosclerosis. 2013;227:349-354.
28. Ishikawa S, Shimano M, Watarai M, et al. Impact of sitagliptin on carotid intima-media thickness in patients with coronary artery disease and impaired glucose tolerance or mild diabetes mellitus. Am J Cardiol. 2014;114:384-388.
29. Shigematsu E, Yamakawa T, Kadonosono K, et al. Effect of sitagliptin on lipid profile in patients with type 2 diabetes mellitus. J Clin Med Res. 2014;6:327-335.
30. Sakamoto Y, Oyama J, Ikeda H, et al. Effects of sitagliptin beyond glycemic control: focus on quality of life. Cardiovasc Diabetol. 2013;12:35.
31. Horton ES, Silberman C, Davis KL, et al. Weight loss, glycemic control, and changes in cardiovascular biomarkers in patients with type 2 diabetes receiving incretin therapies or insulin in a large cohort database. Diabetes Care. 2010;33:1759-1765.
32. Chiquette E, Toth PP, Ramirez G, et al. Treatment with exenatide once weekly or twice daily for 30 weeks is associated with changes in several cardiovascular risk markers. Vasc Health Risk Manag. 2012;8:621-629.
33. Matikainen N, Taskinen MR. The effect of vildagliptin therapy on atherogenic postprandial remnant particles and LDL particle size in subjects with type 2 diabetes. Diabet Med. 2013;30:756-757.
34. Rizzo M, Nikolic D, Banach M, et al. Incretin-based therapies, glucometabolic health and endovascular inflammation. Curr Pharm Des. 2014;20:4953-4960.
35. Rizzo M, Abate N, Chandalia M, et al. Liraglutide reduces oxidative stress and restores heme oxygenase-1 and ghrelin levels in patients with type 2 diabetes: a prospective pilot study. J Clin Endocrinol Metab. 2015;100:603-606.